Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
ACADEMIA
Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
University of Tokyo researchers said on March 18 that their lab study has found that the synthetic serine protease inhibitor nafamostat might efficiently block the invasion of the novel coronavirus into human cells. In Japan, nafamostat is sold by Nichi-Iko…
To read the full story
Related Article
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
- Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
ACADEMIA
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…